INTRODUCTION
Dramatic and rapid improvements in drug elimination efficiency occur during the first months of postnatal development 1, 2 . Yet few clinical pediatric studies have assessed changes in pharmacokinetics during infancy. This lack of specific clinical pharmacokinetic data for the infant population has confounded the design of drug dosage regimens and the assessment of risk associated with drug exposures in infants. A recent review proposes a tentative method to prospectively predict the contribution of hepatic P450-mediated metabolism and renal clearance due to glomerular filtration to infant systemic clearance at any age during the first 6 months following birth 2 .
THEORETICAL FRAMEWORK

Hepatic Clearance
The well-stirred model of hepatic clearance provides a simple model to describe the relationship between the physiological determinants that govern hepatic clearance (1):
(1) In addition to modeling the ontogeny of clearance pathways themselves, pharmacokinetic theory involves considering the extent of drug protein binding to fully appreciate the impact of changes in intrinsic clearance. The current work develops a tentative model to predict the fraction unbound of a specific drug from knowledge of the fraction unbound in adult serum. An estimation of the extent of drug binding to plasma proteins may improve the prediction of drug elimination capacity during infant development.
where Q H represents the hepatic blood flow, ƒ u is the fraction unbound in plasma, and Cl I is intrinsic clearance 12, 13 . These physiological determinants exhibit individual rates and patterns of maturation during infant development. The previous paper 2 focused on modeling the development of enzyme activity as the primary determinant of hepatic clearance in infants. The current paper examines the ability to predict the fraction unbound in infants and children from adult values. 
Protein Binding
The ratio of bound drug concentration (B) to free drug concentration (F) can be written in terms of the number Binding Protein Concentration Ratio of binding sites (n), the molar protein concentration (P), and the affinity constant (K A ), as shown in Equation 2:
Numerous studies have examined the concentration of HSA and AAG in umbilical cord blood. The concentration of HSA is approximately 36 g/L in cord blood compared to 45 g/L in adult plasma [14] [15] [16] [17] [18] [19] [20] . The infant-to-nonpregnantadult concentration ratio for HSA is 0.81 (Table 1) . In pregnant adults, HSA concentrations are lower throughout the later stages of pregnancy and appear to rebound to nonpregnant adult levels by 1 month postpartum 14, 21, 22 , resulting in a ratio of 1.16 ( 
Cord AAG concentrations average 0.24 g/L compared to 0.60 g/L for normal adult plasma 14, 16, 23, 24 , which results in an average ratio of 0.38 for AAG (Table 1) . In contrast to HSA concentrations, AAG concentrations in the mother at delivery are similar to those of nonpregnant adults (Table 1) . Following delivery, AAG concentrations rise and peak around 1 week postpartum 14, 22 . Some studies also show an increase in neonatal serum AAG in the week following delivery 14 .
From a pharmacokinetics perspective, the fraction unbound is more valuable and more frequently reported than is B/F ratios. Fraction unbound drug in the plasma ƒ u is defined as the ratio of F to total drug concentration is the sum of F and B (equation 5). to the HSA data yields a high correlation coefficient (r 2 = 0.970) and an estimate of P infant /P adult of 0.592, which approximates the ratio described earlier ( Table 1 ). The 95% confidence interval (0.535-0.660) does not include unity; hence, incorporating the binding protein concentration ratio proves to be a better model or As the ratio of abundance of binding proteins approaches unity, the fraction unbound in infants approaches adult values. The use of adult intrinsic clearance values may need to be adjusted for differences in binding for highly bound drugs in cases where the plasma protein concentration is significantly lower in infants. to the AAG data yields a modest correlation coefficient (r 2 = 0.713) and an estimate of P infan described earlier for AAG ( Table 1 ). The 95% confidence interval (0.140-0.398) does not incorporate unity, again indicating that Equation 4 is a superior model for predicting B/F in infants. However, Figure 2 clearly shows that the relationship is less robust for AAG than for HSA because of several factors. First, the interindividual variation in AAG concentrations is considerably larger for AAG than for HSA. Second, all of the binding is ascribed to 1 protein in Equation 4 . Most of the AAG-bound drugs are also bound to HSA. Combined with the limited number of observations for AAG, these factors contribute to the uncertainty of the prediction.
Fraction Unbound Prediction
Since protein binding data are more frequently presented and more useful clinically, Table 2 contains the observed and predicted fraction unbound as a function of age and binding protein for infants up to 1 year of age. This approach uses Equation 6 and requires estimates of the predicted binding protein concentration ratio (Figure 1 ) for the respective binding protein and age, as well as the adult fraction unbound, to predict the infant fraction unbound. Overall, the observations with respect to infants hold for plasma obtained from infants of any age. The model incorporating the binding protein ratio appears to more closely mimic the observed fraction unbound in infants than does the fraction unbound in adults alone. Moreover, the fraction unbound for HSA-bound drugs was more readily predicted than that for AAG. 
DISCUSSION
Rapid improvements in drug clearance occur during the first months of postnatal development 1 . However, our understanding of the influence of clearance pathway ontogenesis and drug elimination efficiency in infants remains incomplete because of a lack of specific clinical pharmacokinetic data. We have used in vitro CYP450 activity data in fetal and infant livers and in vivo probe substrates of renal function to develop a general but tentative mathematical model that describes the ontogeny of individual clearance pathways in infants. Although invaluable, this approach is limited without a clear understanding of the ontogenesis of plasma protein binding in this population as well.
The model proposed herein is simple and straightforward. In the absence of direct measurements of plasma protein binding, the fraction unbound in an infant can be predicted from knowledge of the binding characteristics of the drug in adults and the known ontogeny for the binding protein (Figure 1) . Clearly, there is less variability and there are better model predictions for a drug bound mainly to HSA. The enhanced variability associated with AAG is not unexpected given that it is an acute phase reactive protein subject to larger variability than HSA.
It should be noted that, in addition to lower HSA concentration, there is a considerable body of work that suggests that bilirubin and free fatty acids may influence the extent of binding of some drugs in the newborn 14, 20, 22, 25 . For example, Nau et al reported that the elevations in free fatty acids shortly after birth result in increased free fractions of diazepam and its main metabolite 27 . Ehrnebo et al reported that hyperbilirubinemia reduced the binding of a number of acidic drugs 26 . Elevated free fatty acids and bilirubin may explain some of the intersubject variance for a given drug within a population of infants, but these factors do not appear to be a global factor in the present analysis. One of the main assumptions in the model is that the affinity constant is similar in infants and adults. As a first approximation, this assumption appears to be well founded for most drugs, as evidenced by Figure 2 and Table 2 
